A Phase 1 Study of XMT-1536 in Patients with Solid Tumors Likely to Express NaPi2b

A Summary of Dose Escalation

D.L. Richardson[1], E. Hamilton[2], A. Tolcher[3], T.F. Burns[4], W.J. Edenfield[5], K.P. Papadopoulos[6], U.A. Matulonis[7], D. Huebner[8], R. Mosher[8], D. Jarlenski[8], G. Pennock[8], M. Cyr[8], A. Santillan[3], S.V. Ulahannan[1] and K.N. Moore[1]

[1]Stephenson Cancer Center/Sarah Cannon Research Institute at the University of Oklahoma Health Sciences Center, Oklahoma City, OK; [2]Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; [3]NEXT Oncology/Texas Oncology, San Antonio, TX; [4]University of Pittsburgh Medical Center- Hillman Cancer Center, Pittsburgh, PA; [5]Institute of Translational Oncology Research, Prisma Health-Upstate Cancer Institute, Greenville, SC; [6]South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA [8]Mersana Therapeutics Inc, Cambridge, MA

NCT03319628

NaPi2b is an Ideal Antibody-Drug Conjugate Target

Assay Developed to Measure Antigen Expression

- ADC internalizing sodium phosphate transporter; not an oncogene
- Broadly expressed in ovarian cancer and NSCLC adenocarcinoma
- Limited expression in normal tissues
- IHC assay calibrated to distinguish wide range of expression

Epithelial ovarian cancer

H score = 293



Lung adenocarcinoma

H score = 265



Ovarian Cancer Patient-Derived Xenograft Models

Response correlated with NaPi2b Expression



H-score measures the percentage of cells staining multiplied by their intensity (0, 1+, 2+, 3+) for a range of 0 - 300

XMT-1536 is a First-in-Class Dolaflexin ADC

Targets NaPi2b with Controlled Bystander Effect

Hydrophilic Polymer Scaffold

- High drug-to-antibody ratio (DAR) with ~10-12 payloads
- Excellent drug like properties
- Highly stable in circulation
- Dose-proportional exposure
- Very low exposure of free payload



DolaLock Payload with Controlled Bystander Effect

- Selectively toxic to rapidly dividing cells
- Initially released molecule (Auristatin F-HPA) freely cell permeable and bystander capable
- Intracellular conversion to Auristatin F diminishes permeability and controls bystander effect
- Accumulates in tumor, not a PgP substrate
- Induces immunogenic cell death

HPA: Hydroxypropylamide

XMT-1536 Phase 1 Dose Escalation Study Design

Dosing: Q3 weeks

- **DL 6 40 mg/m²** (1.08 mg/kg)
- **DL 5 30 mg/m²** (0.81 mg/kg)
- **DL 4 20 mg/m²** (0.54 mg/kg)
- **DL 3 12 mg/m²** (0.324 mg/kg)
- **DL 2 6 mg/m²** (0.162 mg/kg)
- **DL 1 3 mg/m²** (0.081 mg/kg)

Dosing: Q4 weeks

- **DL 8A 52 mg/m²** (1.4 mg/kg) Ongoing
- **DL 7A 43 mg/m²** (1.2 mg/kg)
- **DL 6A 36 mg/m²** (0.97 mg/kg)
- **DL 5A 30 mg/m²** (0.81 mg/kg)
- **DL 4A 20 mg/m²** (0.54 mg/kg)

Objectives: Evaluate safety and tolerability; determine MTD and identify RP2D; assess preliminary antitumor activity

Patient population: Platinum-resistant, serous ovarian cancer and NSCLC adenocarcinoma progressing after standard treatments*

- Measurable disease per RECIST 1.1
- ECOG 0 or 1
- Archived tissue for retrospective assessment of NaPi2b expression

Dosing: IV initially every 3 weeks, amended to every 4 weeks, until disease progression or unacceptable toxicity

Assessments: Tumor imaging (MRI or CT): baseline and every 2nd cycle; response assessed per RECIST 1.1

MTD = maximum tolerated dose; RP2D = recommended Phase 2 dose
* Dose escalation cohort (DL 3-5/A) also included endometrial, papillary renal, salivary duct, and papillary thyroid cancers

Patient Demographics and Disease Characteristics

Data cut off: 3 Feb 2020

N=59 Patients Dosed at 3 mg/m^2 to 43 mg/m^2					
Age, years; Median (range)			65 (39-93)		
Sex					
Female			48 (81%)		
Male			11 (19%)		
ECOG performance status; n (%)					
0			21 (36%)		
1			38 (64%)		
Primary Tumor Type; n (%)					
Ovarian			37 (64%)		
NSCLC			11 (18%)		
Endometrial			8 (13%)		
Papillary Renal Cancer			2 (3%)		
Salivary Duct			1 (2%)		
Prior lines of Therapy, Median (range)					
All patients			5 (1 to 10)		
Ovarian			5 (1 to 10)		
NSCLC			4 (2 to 6)		
Prior Therapies **Ovarian, N=36*** * One patient prior treatment data not reported yet		**n (%)**	**Prior Therapies** **NSCLC, N=10*** * One patient prior treatment data not reported yet		**n (%)**
	Platinum	36 (100)		Platinum	10 (100)
	Taxane	33 (92)		Pemetrexed	10 (100)
	Bevacizumab	23 (64)		I/O	10 (100)
	PARPi	20 (56)		Taxane	7 (70)
	Investigational	14 (39)		TKI	1 (10)
				Investigational	7 (70)

Treatment-Related Adverse Events Reported in ≥10% of Patients

- 76% (45/59) of Patients experienced a TRAE
- No severe neutropenia, peripheral neuropathy or ocular toxicity
- No G4 or G5 TRAEs
- 4 Treatment-Related SAEs: G1 Pyrexia (possibly), G2 Pyrexia (probably), G3 congestive cardiac failure (possibly), G3 Vomiting (possibly)

	Patients dosed 3 to 40 mg/m^2 N=52				Patients dosed 43 mg/m^2 N=7			
Preferred Term	**Grade 1 n (%)**	**Grade 2 n (%)**	**Grade 3 n (%)**	**Total – All Grades n (%)**	**Grade 1 n (%)**	**Grade 2 n (%)**	**Grade 3 n (%)**	**Total – All Grades n (%)**
NAUSEA	16 (31)	5 (10)	0	21 (40)	1 (14)	1 (14)	0	2 (29)
FATIGUE	7 (13)	13 (25)	0	20 (38)	1 (14)	3 (43)	0	4 (57)
ASPARTATE AMINOTRANSFERASE INCREASED	5 (10)	5 (10)	6 (12)	16 (32)	2 (29)	1 (14)	0	3 (43)
HEADACHE	7 (13)	5 (10)	0	12 (23)	1 (14)	0	0	1 (14)
VOMITING	8 (15)	2 (4)	1 (2)	11 (21)	0	0	0	0
PYREXIA	8 (15)	1 (2)	0	9 (17)	2 (29)	0	0	2 (29)
BLOOD ALKALINE PHOSPHATASE INCREASED	7 (13)	1 (2)	0	8 (15)	0	0	0	0
DECREASED APPETITE	1 (2)	7 (13)	0	8 (15)	0	1 (14)	0	1 (14)
DIARRHEA	5 (10)	1 (2)	1 (2)	7 (13)	1 (14)	0	0	1 (14)
ALANINE AMINOTRANSFERASE INCREASED	5 (10)	1 (2)	0	6 (12)	1 (14)	0	0	1 (14)
ANEMIA	0	3 (6)	2 (4)	5 (10)	1 (14)	1 (14)	0	2 (29)
THROMBOCYTOPENIA	2 (4)	1 (2)	0	3 (6)	2 (29)	1 (14)	0	3 (43)

Data cut-off: 3 Feb 2020

Well Tolerated to Date. No DLT at Highest Completed Dose Level of 43 mg/m^2 q4w

Dose Level (DL)	Dose	Tumor Types	Pts / DL	DLT Description, Number of Patients with Event
1	3 mg/m^2 q3w	Ovarian	1	
2	6 mg/m^2 q3w	Ovarian	1	
3	12 mg/m^2 q3w	Ovarian (1) NSCLC (2) Endometrial (3) Papillary Renal (1)	7	
4/4A	20 mg/m^2 q3w/q4w	Ovarian (11) NSCLC (1) Endometrial (1) Salivary Duct (1) Papillary renal (1)	15	
5/5A	30 mg/m^2 q3w/q4w	Ovarian (12) NSCLC (3) Endometrial (4)	19	Transient G3 AST; resolved to G1 within 21 days; n=1
6	40 mg/m^2 q3w	Ovarian (1)	1	Transient G3 AST; resolved to G1 within 21 days; n=1
6A	36 mg/m^2 q4w	Ovarian (7) NSCLC (1)	8	G2 AST/G1 ALT preventing 2nd dose & causing study discontinuation; n=1
7A	43 mg/m^2 q4w	Ovarian (3) NSCLC (4)	7	

Data cut-off: 3 Feb 2020

Favorable Dose- and Biomarker-Response Relationship

Emerging Data Will Define Biomarker Cut-Off for Patient Selection in Future Studies

Response - Ovarian Cancer and NSCLC adenocarcinoma N=39*		N (%)
		All
20 mg/m^2	N	10
	PR	**1 (10%)**
	SD	6 (60%)
	DCR (PR+SD)	**7 (70%)**
30, 36, 40 mg/m^2	N	22
	PR	**3 (14%)**
	SD	10 (45%)
	DCR (PR+SD)	**13 (59%)**
43 mg/m^2	N	7
	PR	**2 (29%)**
	SD	4 (57%)
	DCR (PR+SD)	**6 (86%)**

Data cut-off: 3 Feb 2020

*Excludes 3 patients discontinued due to investigator/patient choice and 1 without RECIST scan

**Hypocellular specimen/indeterminate for H-score or not determined yet

Favorable Dose- and Biomarker-Response Relationship

Emerging Data Will Define Biomarker Cut-Off for Patient Selection in Future Studies

Response - Ovarian Cancer and NSCLC adenocarcinoma N=39*		N (%)	
		All	**Higher NaPi2b ᵒ**
20 mg/m²	N	10	7
	PR	**1 (10%)**	**0 (0%)**
	SD	6 (60%)	4 (57%)
	DCR (PR+SD)	**7 (70%)**	**4 (57%)**
30, 36, 40 mg/m²	N	22	12
	PR	**3 (14%)**	**3 (25%)**
	SD	10 (45%)	6 (50%)
	DCR (PR+SD)	**13 (59%)**	**9 (75%)**
43 mg/m²	N	7	3
	PR	**2 (29%)**	**2 (67%)**
	SD	4 (57%)	0 (0%)
	DCR (PR+SD)	**6 (86%)**	**2 (67%)**

PR: 33%
DCR: 73%

Data cut-off: 3 Feb 2020

*Excludes 3 patients discontinued due to investigator/patient choice and 1 without RECIST scan ᵒ Higher NaPi2b Expression: at / above lowest H-score at which response observed (≥110)

**Hypocellular specimen/indeterminate for H-score or not determined yet ᵒᵒ Lower NaPi2b Expression: below the lowest H-score at which response observed (<110)

Favorable Dose- and Biomarker-Response Relationship

Emerging Data Will Define Biomarker Cut-Off for Patient Selection in Future Studies

Response - Ovarian Cancer and NSCLC adenocarcinoma N=39*		N (%)		
		All	**Higher NaPi2b [o]**	**Lower NaPi2b [oo]**
20 mg/m²	N	10	7	2
	PR	**1 (10%)**	**0 (0%)**	**0 (0%)**
	SD	6 (60%)	4 (57%)	2 (100%)
	DCR (PR+SD)	**7 (70%)**	**4 (57%)**	**2 (100%)**
30, 36, 40 mg/m²	N	22	12	7
	PR	**3 (14%)**	**3 (25%)**	**0 (0%)**
	SD	10 (45%)	6 (50%)	3 (43%)
	DCR (PR+SD)	**13 (59%)**	**9 (75%)**	**3 (43%)**
43 mg/m²	N	7	3	2
	PR	**2 (29%)**	**2 (67%)**	**0 (0%)**
	SD	4 (57%)	0 (0%)	2 (100%)
	DCR (PR+SD)	**6 (86%)**	**2 (67%)**	**2 (100%)**

PR: 0%
DCR: 55%

Data cut-off: 3 Feb 2020

*Excludes 3 patients discontinued due to investigator/patient choice and 1 without RECIST scan
**Hypocellular specimen/indeterminate for H-score or not determined yet

[O] Higher NaPi2b Expression: at / above lowest H-score at which response observed (≥110)
[OO] Lower NaPi2b Expression: below the lowest H-score at which response observed (<110)

Favorable Dose- and Biomarker-Response Relationship

Emerging Data Will Define Biomarker Cut-Off for Patient Selection in Future Studies

Response - Ovarian Cancer and NSCLC adenocarcinoma N=39*		N (%)			
		All	**Higher NaPi2b [o]**	**Lower NaPi2b [oo]**	**Indeterm NaPi2b ****
20 mg/m²	N	10	7	2	1
	PR	**1 (10%)**	**0 (0%)**	**0 (0%)**	**1 (100%)**
	SD	6 (60%)	4 (57%)	2 (100%)	0 (0%)
	DCR (PR+SD)	**7 (70%)**	**4 (57%)**	**2 (100%)**	**1 (100%)**
30, 36, 40 mg/m²	N	22	12	7	3
	PR	**3 (14%)**	**3 (25%)**	**0 (0%)**	**0 (0%)**
	SD	10 (45%)	6 (50%)	3 (43%)	1 (33%)
	DCR (PR+SD)	**13 (59%)**	**9 (75%)**	**3 (43%)**	**1 (33%)**
43 mg/m²	N	7	3	2	2
	PR	**2 (29%)**	**2 (67%)**	**0 (0%)**	**0 (0%)**
	SD	4 (57%)	0 (0%)	2 (100%)	2 (100%)
	DCR (PR+SD)	**6 (86%)**	**2 (67%)**	**2 (100%)**	**2 (100%)**

Data cut-off: 3 Feb 2020

*Excludes 3 patients discontinued due to investigator/patient choice and 1 without RECIST scan [O] Higher NaPi2b Expression: at / above lowest H-score at which response observed (≥110)

**Hypocellular specimen/indeterminate for H-score or not determined yet [OO] Lower NaPi2b Expression: below the lowest H-score at which response observed (<110)

Responses and Stable Disease Observed at Higher Doses and Higher NaPi2b Expression

Best Percent Change in Sum of Target Lesion Dimensions from Baseline**



* Best overall response of progressive disease

**Excludes 3 patients discontinued due to investigator/patient choice and 1 without RECIST scan

***Hypocellular specimen/indeterminate for H-score or not determined yet

Data cut-off: 3 Feb 2020

Durations at ≥ 20mg/m² - Longer Treatment Duration Observed in Patients with Higher NaPi2b Expression







Data cut-off: 3 Feb 2020

Patient with Ovarian Cancer – Confirmed PR with 62% Tumor Reduction

Platinum Resistant Ovarian Cancer Patient Treated with 43mg/m^2	
Age	43
# prior regimens	9
CA125 Baseline (U/mL)	5409
CA125 after 3 Cycles (U/mL)	427
NaPi2b IHC, H-Score	110

Baseline



After 3 Cycles



- Prior treatments with carboplatin, paclitaxel, cisplatin, liposomal doxorubicin, gemcitabine, bevacizumab, olaparib
- PR detected at Cycle 2 and confirmed at Cycle 3

Patient with NSCLC – Confirmed PR with 40% Tumor Reduction

NSCLC Adenocarcinoma Patient Treated with 43 mg/m^2	
Age	80
# prior regimens	4
NaPi2b IHC, H-Score	245



- Prior treatments with carboplatin, pemetrexed, paclitaxel, nivolumab
- PR detected at Cycle 2 and confirmed at Cycle 3

Conclusions

- XMT-1536 has a favorable safety profile
  - Most treatment related adverse events (TRAEs) were Grade 1 or 2
  - Nausea, fatigue, transient increase in AST, headache, and vomiting were the most frequent TRAEs
  - No severe neutropenia, peripheral neuropathy or ocular toxicity
- 52 mg/m^2 dose escalation cohort under evaluation
- Antitumor activity observed in heavily pretreated patients with PROC and NSCLC adenocarcinoma (median of 5 prior lines of therapy)
  - Higher response rate at doses $\geq$30 mg/m^2
  - Higher response rate in patients with higher NaPi2b expression; No responses in patients with lower NaPi2b expression
  - Literature suggests low single digit response rates in platinum-resistant ovarian cancer with similar lines of therapy[1,2,3]
- Expansion at 36 and 43 mg/m^2 q 4 weeks is ongoing in PROC and NSCLC adenocarcinoma

[1]Bruchim, Eur J Obs&Gyn and Repro Biology 2013;166:94-98
[2]Griffiths, Int J Gynecol Cancer 2011;21:58-65
[3]Hoskins, Gynecologic Onc 2005;97:862-869

Acknowledgements

We thank the patients, their families and caregivers for their contribution to this study*

UNTED STATES
U. of Alabama at Birmingham, Birmingham, AL – Rebecca Ahrend
Arizona Oncology Associates, Tucson, AZ – Joseph Buscema
Rocky Mountain Cancer Centers, LLP, Lone Tree, CO – Robert Jotte
H. Lee Moffitt Cancer Center, Tampa FL – Julian Santos
U. of Florida, Gainesville, FL – Frederic Kaye
U. of Miami, Miller School of Medicine, Miami, FL – Marilyn Huang
Lahey Clinic, Burlington, MA – Corrine Zarwan
Massachusetts General Hospital, Boston, MA – Sara Bouberhan
Dana Farber Cancer Institute, Boston, MA – Ursula Matulonis; Pasi Janne
Maryland Oncology and Hematology, Bethesda, MD – John Wallmark
Henry Ford Medical Center, Detroit, MI – Ding Wang
QUEST Research Institute, Farmington Hills, MI – Mohammed Ibrahim
St. Luke's Cancer Center, Kansas City, MO – Ram Subramanian
Washington University of . St. Louis, St. Louis, MO – Premal Thacker
U. of Utah Huntsman Cancer Institute – Theresa Werner
Atrium Health, Charlotte, NC – William Naumann
Mount Sinai, NYC, NY – Thomas Marron
Ohio State University Wexner Medical Center, Columbus, OH – John Hays
U. of Oklahoma, Oklahoma City, OK – Debra Richardson; Susanna Ulahannan
Willamette Valley Cancer Institute, Eugene, OR – Charles Anderson
Fox Chase Cancer Center, Philadelphia, PA – Martin Edelman

UNITED STATES
UPMC Hillman Cancer Center, Pittsburgh, PA – Tim Burns
Allegheny Health Network, Pittsburgh, PA – Thomas Krivak
Institute of Translational Oncology Research, Greenville, SC – Jeffrey Edenfield
Sarah Cannon Research Institute, Nashville, TN – Erika Hamilton; Melissa Johnson
U. of Texas Southwestern Medical School, Dallas, TX – David Miller
Texas Oncology Fort Worth, Fort Worth, TX – Stephen Richey
Texas Oncology, Houston, TX – Donald Richards
Texas Oncology, Austin, TX – Jason Melear
Mary Crowley Cancer Research Institute, Dallas, TX – Minal Barve
START, San Antonio, TX – Kryi Papadopoulos
NEXT Oncology, San Antonio, TX – Anthony Tolcher, Antonio Santillan
Virginia Cancer Specialist, Fairfax, VA – Alex Spira

CANADA
Southlake Regional Health Care Center, Newmarket, Ontario – Labib Zibdawi
British Columbia Cancer Agency, Vancouver – Sara Taylor
Jurasinski Caner Center, Hamilton, Ontario – Hirte Holgar

AUSTRALIA
Chris O'Brien Lifehouse, Camperdown – Steven Kao
Peter MacCallum Center, Melbourne, Victoria – Linda Milschkin
Austin Health – ONJ Cancer Center, Heidelberg, Victoria – Paul Mitchell

***Sponsored by Mersana Therapeutics, Inc.**